Abstract
Subcutaneous allergen immunotherapy (SCIT) decreases allergic and local allergic rhinitis (AR and LAR, respectively) symptoms. In AR patients also induces a sustained effect lasting several years after therapy withdrawal. Whether SCIT has a comparable long-lasting effect in LAR is currently unknown. We evaluated the long-term evolution of LAR patients with a 3-year SCIT treatment with Dermatopagoidespteronyssinus (DP) (DP-SCIT), as compared to AR subjects.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
